Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ownership Breakdown Lineage Cell Therapeutics, Inc. LCTX

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for...


Top institutional share ownership of Lineage Cell Therapeutics Inc

Name Shares Shares % change Value Value % change
Broadwood Capital Inc 34,935,485 0.0% $39,477 -28.5%
Vanguard Group Inc 5,951,493 0.0% $6,726 -28.5%
Defender Capital, LLC. 5,093,535 -1.8% $5,959 1.7%
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares 3,973,146 0.0% $4,490 -28.5%
BlackRock Inc. 3,704,387 -1.4% $4,186 -29.5%
Laurion Capital Management LP 2,377,940 -1.8% $2,687 -29.8%
Raffles Associates Lp 2,080,536 7.8% $2,351 -22.9%
Prescott General Partners LLC 1,851,851 0.0% $2,093 -28.5%
VEXMX - Vanguard Extended Market Index Fund Investor Shares 1,704,495 0.0% $1,926 -28.5%
IBB - iShares Nasdaq Biotechnology ETF 1,318,499 -1.2% $1,490 -29.3%

Top institutional buyers of Lineage Cell Therapeutics Inc

Name Shares % change Value % change Shares Value
Connor, Clark & Lunn Investment Management Ltd. 113.0% 52.3% 288,299 $326
MAI Capital Management 110.7% 50.9% 521,870 $590
Etf Managers Group, Llc 8.2% -24.0% 329,826 $373
ITEQ - BlueStar Israel Technology ETF 8.2% -22.7% 329,826 $373
Raffles Associates Lp 7.8% -22.9% 2,080,536 $2,351
Geode Capital Management, Llc 0.1% -28.4% 1,251,156 $1,413

Top institutional sellers of Lineage Cell Therapeutics Inc

Name Shares % change Value % change Shares Value
Millennium Management Llc -50.4% -64.5% 506,313 $572
BRUSX - Ultra-Small Company Fund Class N -40.2% -57.3% 227,000 $257
Bridgeway Capital Management Inc -38.7% -56.2% 241,666 $273
Jpmorgan Chase & Co -16.5% -40.3% 1,049,051 $1,185
Ergoteles LLC -11.3% -36.6% 490,895 $555
IWC - iShares Micro-Cap ETF -3.1% -30.9% 258,393 $292
Laurion Capital Management LP -1.8% -29.8% 2,377,940 $2,687
Defender Capital, LLC. -1.8% 1.7% 5,093,535 $5,959
BlackRock Inc. -1.4% -29.5% 3,704,387 $4,186
IBB - iShares Nasdaq Biotechnology ETF -1.2% -29.3% 1,318,499 $1,490

Information provided by Fintel.io